Lebrikizumab-Lbkz
EBGLYSS
Interleukin-13 Antagonist
NADAC/unit
$1795.8056
No Shortage
Tier 1: 1.8%
PA Req: 8.5%
vs. brand EBGLYSS: Generic saves up to -17858% per unit
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.